Equities research analysts forecast that Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) will post $2.10 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Neovasc’s earnings. The lowest sales estimate is $800,000.00 and the highest is $3.40 million. Neovasc reported sales of $520,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 303.8%. The business is expected to report its next earnings report on Thursday, March 19th.
According to Zacks, analysts expect that Neovasc will report full year sales of $3.85 million for the current financial year, with estimates ranging from $2.30 million to $5.40 million. For the next year, analysts anticipate that the firm will report sales of $7.65 million, with estimates ranging from $3.50 million to $11.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Neovasc.
A number of brokerages have recently weighed in on NVCN. Zacks Investment Research upgraded shares of Neovasc from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Wednesday, November 13th. HC Wainwright set a $9.00 target price on shares of Neovasc and gave the company a “buy” rating in a report on Monday, November 4th.
Large investors have recently made changes to their positions in the company. Magnetar Financial LLC lifted its stake in shares of Neovasc by 325.3% in the 2nd quarter. Magnetar Financial LLC now owns 4,809,269 shares of the medical equipment provider’s stock valued at $2,322,000 after acquiring an additional 3,678,404 shares during the last quarter. Citadel Advisors LLC bought a new position in Neovasc during the 2nd quarter worth approximately $36,000. Finally, Bank of Montreal Can grew its position in Neovasc by 72.7% during the 2nd quarter. Bank of Montreal Can now owns 51,807 shares of the medical equipment provider’s stock worth $250,000 after acquiring an additional 21,807 shares during the last quarter. 15.04% of the stock is currently owned by hedge funds and other institutional investors.
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.